Key facts
- This page summarizes Adam Kaplin's Form 3 filing for MIRA PHARMACEUTICALS, INC. (MIRA).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Aug 2023, 17:55.
Adam Kaplin - 02 Aug 2023 Form 3 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)
- Reporting relationship
- Pres. & Chief Scientific Off.
- Issuer ticker
- MIRA
- Reported as of
- 02 Aug 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 02 Aug 2023, 17:55:32 UTC
- Prior SEC filing
- 09 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michelle Yanez, Attorney-in-Fact for Adam Kaplin
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Adam Kaplin filed Form 3 for MIRA PHARMACEUTICALS, INC. (MIRA) on 02 Aug 2023.
Change
- Previous filing in this sequence was filed on 09 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MIRA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 200,000
- Date
- 02 Aug 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MIRA
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $5.00
- Footnotes
- F1
MIRA
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $5.00
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option vested and became exercisable as to 50,000 shares on June 15, 2022 and 50,000 shares on June 15, 2023. 50,000 shares will become exercisable on June 15, 2024 and 50,000 shares will become exercisable on June 15, 2025.
Footnote F2
The option vested and became exercisable as to 13,334 shares on April 28, 2023, and becomes exercisable on the remaining 13,333 shares on April 28, 2024 and 13,333 shares on April 28, 2025.